Introduction
Most cell-surface proteins are comprised of different combinations of a limited set of protein domains. These include small modules such as the epidermal growth-factor-like (EGF) and short consensus-repeat (SCR) domains, which are both less than 60 aminoacid residues long and frequently occur as multiple repeats. Structural studies (Rao et al., 1995; Downing et al., 1996; Casasnovas et al., 1999) have shown that SCR and EGF modules fold to form all--strand domains that are strengthened by two and three disul®de bonds, respectively.
The EGF module is widely distributed among extracellular proteins involved in adhesion, receptor±ligand interactions, extracellular matrix structure, determination of cell fate and blood coagulation (Campbell & Bork, 1993) . A subset of EGF domains contains a Ca 2+ -binding (cb) consensus sequence (Rees et al., 1988; Handford et al., 1991; Mayhew et al., 1992) . The Ca 2+ ion is thought to be important for the orientation of cbEGF pairs by restricting the conformational¯exibility of interdomain linkages, as shown for ®brillin-1 (Werner et al., 2000) . The solution structures of pairs of cbEGF domains from ®brillin-1 show the two domains in an extended rod-like conformation (Downing et al., 1996; Smallridge et al., 2003) . Meanwhile, the crystal structure of three contiguous EGF domains, 4±6, from thrombomodulin (in complex with thrombin) shows a Y-shaped fragment. Thrombomodulin EGF domains 4 and 6 fold similarly to other EGF-like domains with the usual (1±3, 2±4, 5±6) disul®de pairing, while the central 5 domain has an unusual (1±2, 3±4, 5±6) disul®de pairing and diverges strongly from archetypal EGF structures.
SCR domains are also known as complement protein (CP) modules; they are frequently found as components of complement-system proteins (Wiles et al., 1997) . Indeed, many of the complement regulatory proteins (e.g. CD46 and CD55) and complement receptors (e.g. CD21 and CD35) consist entirely of repeated SCR domains. However, SCR domains have been identi®ed in over 50 distinct mammalian proteins. Multiple SCR domains occur in tandem, separated by three to ®ve amino acids, and two to four contiguous SCR modules are believed to be required to form a ligand-binding site. The solution structures of individual (Norman et al., 1991; Barlow et al., 1992) and pairs (Barlow et al., 1993; Wiles et al., 1997) of SCR modules exist as well as the crystal structure of the four SCR domains of CD55 (Lukacik et al., 2004) , Vaccinia virus complement-control protein (Murthy et al., 2001 ) and 2-glycoprotein I (Schwarzenbacher et al., 1999) . These reveal that consecutive SCR modules form elongated structures.
EMR2 and CD97 are members of the EGF-TM7 family of proteins with between three and ®ve consecutive EGF modules linked to a seven-span transmembrane class B G-proteincoupled receptor (GPCR) via a mucin-like spacer domain (Hamann et al., 1995; Lin et al., 2000) . The EGF domains of EMR2 and CD97 are highly homologous, with 95±100% sequence identity in corresponding EGF domains. Of the 236 amino-acid residues in the ®ve domain isoforms, only two residues in domain 1, one residue in domain 2 and three residues in domain 3 differ between EMR2 and CD97. Domains 4 and 5 are 100% identical.
crystallization papers
Signi®cant sequence homology between EMR2 and CD97 also extends to the mucinlike stalk region (46%), the 7TM region (45%) and multiple potential N-and O-glycosylation sites within the extracellular domain. EGF domains 2±5 in both EMR2 and CD97 are of the Ca 2+ -binding type. Both EMR2 and CD97 molecules are highly expressed in immune tissues (Lin et al., 2000) . EMR2 is restricted to monocytes/ macrophages and granulocytes, while CD97 is ubiquitously expressed in most cell types. Notably, CD97 is rapidly up-regulated in activated T and B cells. Their function is largely unknown. Based on unique hybrid structures and restricted expression patterns, it is thought that they may play a role in the immune system by interacting with either cell-surface or extracellular matrix proteins. CD55 (or decay-accelerating factor, DAF) has been shown to be a biological ligand of CD97 (Hamann et al., 1996) , demonstrating that these molecules do have the potential to act as cell-adhesion molecules. They are also likely to have a signalling role, given that class B GPCRs are known to signal via G-protein activation in response to peptide-ligand binding. However, G-protein-mediated signalling by EGF-TM7s still awaits functional demonstration.
The biological ligand of CD97, CD55, consists of four N-terminal SCR domains that are attached to many mammalian cell types via a heavily O-glycosylated spacer that is linked to a C-terminal glycosylphosphatidylinositol (GPI) anchor (Lublin & Atkinson, 1989) . It is important for complement regulation (Brodbeck et al., 2000) and cell signalling (Hamann et al., 1996) . CD97±CD55 binding is mediated exclusively by protein±protein interactions of the EGF and SCR modules located at the N-terminus of each protein (Lin et al., 2001 ). The interaction is Ca 2+ -dependent and the CD97 splice variant with the highest af®nity comprises three EGF domains: 1, 2 and 5 (143 residues in total, compared with the 236 residues of the ®ve-domain isoform). EMR2 also binds CD55, but with a K d at least one order of magnitude weaker than that of CD97. This is despite the fact that the two proteins differ by only three amino acids within the three EGF domains. The precise role of the CD97±CD55 interaction is still unknown. It may possibly be involved in adhesion and signalling within the in¯am-matory and immune responses (Gray et al., 1996) ; for example, both CD97 and CD55 are present in arthritic joints (Hamann et al., 1999) . Other studies have suggested that CD97±CD55 complex may play a role in cell migration and co-stimulation during multiple sclerosis (MS; Visser et al., 2002) .
In the present study, the crystallization and preliminary crystallographic analysis of three extracellular EGF domains (EGF-1,2,5) of EMR2 are reported. The function of EGF-containing molecules is dependent on the relative orientations of the multiple domains and, to date, most structural information is limited to pairs. This will be the ®rst structure of three consecutive archetypal EGF domains (unlike thrombomodulin) and therefore will prove particularly useful in increasing understanding of the structure±function relationship. With the structure of CD55 (Lukacik et al., 2004) , it could also be used to model the binding interaction between EMR2 and CD55, thus furthering understanding of why EGF and SCR modules are so well suited for protein interactions, which is currently hindered by the complete lack of structures of EGF±SCR complexes.
Protein expression and purification
The three extracellular EGF domains (EGF-1,2,5; isoform E; residues 25±167) of the CD55-binding splice variant of EMR2 (15 579 Da) were expressed in Escherichia coli using a His 6 -tag-based inducible expression system as previously described (Lin et al., 2001) . Following Ni 2+ af®nity puri®cation under denaturing conditions, peptides were reduced, puri®ed and refolded according to a well established in vitro refolding protocol (Handford et al., 1991) . After puri®cation, EMR2 was lyophilized, reconstituted into water and concentrated to 68.6 mg ml
À1
. The concentration was con®rmed using the calculated extinction coef®cient at 280 nm (21 000 M À1 cm
computed from the amino-acid composition using the EXPASY server; Appel et al., 1994) .
Crystallization
Crystallization was performed using the sitting-drop vapour-diffusion method at 298 K in 16-well plates. Drops were prepared by mixing 1 ml of protein solution with an equal volume of crystallization solution and were equilibrated against 300 ml crystallization solution. Conditions were screened using Crystal Screen reagent kits (Hampton Research). Initial leads were followed and rod-shaped native EMR2 crystals were obtained using 0.1±0.175 M calcium acetate, 12±16%(w/v) PEG 8000, 0.1 M sodium cacodylate buffer pH 6.5.
The inclusion of Ca 2+ in the crystallization conditions for EMR2 suggested co-crystallization as a possibility for heavy-atom derivatization. Lanthanide metals are recommended Ca 2+ replacements and a variety were tested, along with several other divalent cations. EMR2 co-crystals were successfully grown in the presence of both 0.1±0.125 M barium chloride (Fig. 1) and 0.1 M strontium chloride. 
Ba
2+ crystals of EGF domains 1, 2 and 5 from EMR2 (300 mm in the longest direction). (Matthews, 1968) , is 2.8 A Ê 3 Da À1 , assuming two molecules in the asymmetric unit. This value corresponds to a solvent content of 56%. The Ba 2+ and Sr 2+ crystals also belong to space group P2 1 and have very similar parameters to the Ca 2+ crystals. Full details of data-collection and processing statistics for all crystals are presented in Table 1 .
An anomalous difference Patterson calculated at Harker section v = 0.5 between 10 and 2.6 A Ê from the Ba 2+ crystal data (Fig. 2) 2+ crystal data. The map is contoured from 1.5' in 0.5' intervals. Main peaks, labelled 1 (6.6'), 2 (4.7') and 3 (5.3'), are the selfpeaks corresponding to the three Ba atoms.
